3T-403
/ 3T Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 26, 2025
Breaking down solid tumor barriers with a bispecific T cell engager against a novel pHLA target [WITHDRAWN]
(AACR 2025)
- "3T-403, a CD3 bispecific T cell engager utilizing a T cell receptor mimic (TCRm) antibody has been developed to this novel target...Investigational new drug (IND) application completion is expected early 2026. Such a bispecific T cell engager against a novel target shows significant promise to address multiple solid tumor indications."
IO biomarker • Breast Cancer • Colorectal Cancer • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer
1 to 1
Of
1
Go to page
1